The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
Lutio has the potential to offer significant cost savings when available to UK patients.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
3D CMOS chip for connecting electroactive tissues and organoids to software
Today, India stands at 1.7 nurses per 1,000 population, as opposed to the World Health Organization norm of 3 nurses per 1000.
Subscribe To Our Newsletter & Stay Updated
